1. From 1999 to 2016, more than ____________people have died in the U.S. from overdoses related to prescription opioids.
A. 100,000
B. 150,000
C. 200,000
D. <50,000
2. Which states had the highest observed age-adjusted drug overdose death rates in 2016?
A. West Virginia, Ohio, the District of Columbia and Pennsylvania
B. Pennsylvania, New York, New Jersey
C. California, Texas, Florida, and New York
D. Florida, Ohio, the District of Columbia and Pennsylvania
3. Manufacturer must report to DEA when it concludes:
A. that there is no risk of diversion
B. that information indicates that a downstream registrant poses a risk of diversion
C. that information indicates that an employee poses a risk of diversion
D. Manufactures have no obligation to report to the DEA
4. In relation to a recent distributor settlement involving Cardinal in 2016, allegations included which of the following:
A. failure to report suspicious orders in certain states and failing to maintain adequate records in certain states
B. failure to conduct and monitor internal training and compliance
C. failure to properly assist pharmacists in the dispensing process
D. none of the above
5. In a 2017 case involving Safeway for $3 million, allegations included:
A. failure to report suspicious orders in certain states and failing to maintain adequate records in certain states
B. failure to conduct and monitor internal training and compliance
C. failure to properly assist pharmacists in the dispensing process
D. failing to timely report missing or stolen controlled substances
6. For both the pharmacist and pharmacy technician role, which of the following is an implication of recent enforcement actions?
A. Proper record keeping
B. Internal training is not important
C. Improper handling of controlled substances
D. Identifying concerns and reporting them is not important
Evaluation Questions
7. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
8. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
9. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
10. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
11. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Will the information presented cause you to change your practice?
A. Yes
B. No
19. Are you committed to making these changes?
A. Yes
B. No
20. As a result of this activity, did you learn something new?
A. Yes
B. No
21. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
22. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20